Comparison of a rapid fluorescence immunochromatographic test with an enzyme-linked immunosorbent assay for measurement of SARS-CoV-2 spike protein antibody neutralizing activity

Filippatos, Filippos; Tatsi, Elizabeth‐Barbara; Papagiannopoulos, C; Syriopoulou, Vasiliki; Michos, Athanasios

doi:10.1016/j.jviromet.2023.114728

Cited by 1 publication

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The enzyme-linked immunosorbent assay (ELISA) could be an alternative method for assessing neutralizing antibodies in people receiving COVID-19 vaccines . They use the principle of blocking neutralizing antibodies and the receptor binding domain (RBD), thereby inhibiting the binding between RBD and angiotensin-converting enzyme 2 (ACE2). , Unfortunately, this method takes more than 1 h for antibody assessment and also requires the expertise of operators. Therefore, devices that are easy to use and rapidly produce results have attracted attention for neutralizing antibody assays.…”

Section: Introductionmentioning

confidence: 99%

Overlaid Lateral Flow Immunoassay for the Simultaneous Detection of Two Variant-Specific SARS-CoV-2 Neutralizing Antibodies

Deenin,

Khongchareonporn,

Ruxrungtham

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

vaccines have been provided to the general public to build immunity since the 2019 coronavirus pandemic. Once vaccinated, SARS-CoV-2 neutralizing antibodies (NAbs-COVID-19) are needed for excellent protection against COVID-19. However, monitoring NAbs-COVID-19 is complicated and requires hospital visits. Moreover, the resulting NAbs-COVID-19 are effective against different strains of COVID-19 depending on the type of vaccine received. Here, an overlaid lateral flow immunoassay (O-LFIA) was developed for the simultaneous detection of two NAbs-COVID-19 against different virus strains, Delta and Omicron. The O-LFIA was visualized with two T-lines with a single device using competition between the free antigen and the antigen-binding antibody. Angiotensin-converting enzyme 2 (ACE2) immobilized on the T-line binds to the antigen remaining after antibody binding. Under the optimum conditions, the proposed device exhibited 50% inhibition concentrations (IC 50 values) of 45.1 and 53.6 ng/mL for the Delta and Omicron variants, respectively. Additionally, the proposed platform was applied to realworld samples of animal and human serum, and the developed immunoassay provided results that were in good agreement with those obtained with the standard method. In conclusion, this developed O-LFIA can be used as an alternative method to detect NAbs-COVID-19 and can be enabled for future advancements toward commercialization.

show abstract

Section: Introductionmentioning

confidence: 99%